Your browser doesn't support javascript.
loading
Myeloma Genome Project Panel is a Comprehensive Targeted Genomics Panel for Molecular Profiling of Patients with Multiple Myeloma.
Sudha, Parvathi; Ahsan, Aarif; Ashby, Cody; Kausar, Tasneem; Khera, Akhil; Kazeroun, Mohammad H; Hsu, Chih-Chao; Wang, Lin; Fitzsimons, Evelyn; Salminen, Outi; Blaney, Patrick; Czader, Magdalena; Williams, Jonathan; Abu Zaid, Mohammad I; Ansari-Pour, Naser; Yong, Kwee L; van Rhee, Frits; Pierceall, William E; Morgan, Gareth J; Flynt, Erin; Gooding, Sarah; Abonour, Rafat; Ramasamy, Karthik; Thakurta, Anjan; Walker, Brian A.
Afiliação
  • Sudha P; Melvin and Bren Simon Comprehensive Cancer Center, Division of Hematology Oncology, Indiana University School of Medicine, Indiana University, Indianapolis, Indiana.
  • Ahsan A; Translational Medicine, Bristol Myers Squibb, Summit, New Jersey.
  • Ashby C; Department of Biomedical Informatics, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas.
  • Kausar T; Translational Medicine, Bristol Myers Squibb, Summit, New Jersey.
  • Khera A; Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom.
  • Kazeroun MH; MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom.
  • Hsu CC; Translational Medicine, Bristol Myers Squibb, Summit, New Jersey.
  • Wang L; Department of Pathology and Laboratory Research, Indiana University School of Medicine, Indiana University, Indianapolis, Indiana.
  • Fitzsimons E; Cancer Institute, University College London, London, United Kingdom.
  • Salminen O; MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom.
  • Blaney P; Perlmutter Cancer Center, NYU Langone Medical Center, New York, New York.
  • Czader M; Department of Pathology and Laboratory Research, Indiana University School of Medicine, Indiana University, Indianapolis, Indiana.
  • Williams J; Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom.
  • Abu Zaid MI; Melvin and Bren Simon Comprehensive Cancer Center, Division of Hematology Oncology, Indiana University School of Medicine, Indiana University, Indianapolis, Indiana.
  • Ansari-Pour N; MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom.
  • Yong KL; Cancer Institute, University College London, London, United Kingdom.
  • van Rhee F; Myeloma Center, Winthrop P. Rockefeller Cancer institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas.
  • Pierceall WE; Translational Medicine, Bristol Myers Squibb, Summit, New Jersey.
  • Morgan GJ; Perlmutter Cancer Center, NYU Langone Medical Center, New York, New York.
  • Flynt E; Translational Medicine, Bristol Myers Squibb, Summit, New Jersey.
  • Gooding S; Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom.
  • Abonour R; MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom.
  • Ramasamy K; Oxford Center for Translational Myeloma Research, University of Oxford, Oxford, United Kingdom.
  • Thakurta A; Melvin and Bren Simon Comprehensive Cancer Center, Division of Hematology Oncology, Indiana University School of Medicine, Indiana University, Indianapolis, Indiana.
  • Walker BA; Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom.
Clin Cancer Res ; 28(13): 2854-2864, 2022 07 01.
Article em En | MEDLINE | ID: mdl-35522533
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Mieloma Múltiplo Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Mieloma Múltiplo Idioma: En Ano de publicação: 2022 Tipo de documento: Article